The bispecific innate cell engager AFM28 eliminates CD123+ leukemic stem and progenitor cells in AML and MDS



Summary

AFM28, a bispecific innate cell engager targeting CD123 and CD16A, demonstrates promising results in eliminating leukemic stem and progenitor cells (LSPCs) expressing CD123 in acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS). By engaging natural killer (NK) cells via CD16A, AFM28 effectively redirects NK cell cytotoxicity towards CD123+ leukemic cells, including treatment-resistant LSPCs. Preclinical studies demonstrate AFM28’s ability to induce significant LSPC depletion in vitro and in vivo, suggesting its potential as a novel immunotherapeutic approach for targeting the root of AML and MDS and potentially overcoming treatment resistance. This targeted elimination could lead to improved disease control and durable remissions.

Read more…

Credits: Source

This post is part of “Science/Immunology News”, Follow for more…!!!